U.S. markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.67+0.16 (+0.65%)
At close: 4:00PM EDT

24.67 0.00 (0.00%)
After hours: 6:30PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close24.51
Open24.51
Bid24.60 x 1200
Ask24.67 x 800
Day's Range24.30 - 24.93
52 Week Range18.18 - 27.80
Volume1,561,203
Avg. Volume1,907,990
Market Cap7.724B
Beta (5Y Monthly)1.05
PE Ratio (TTM)70.49
EPS (TTM)0.35
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
35% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)
    Motley Fool

    3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)

    Over the long run, value stocks have outperformed growth stocks on an annualized basis. Historically low lending rates and a highly accommodative Federal Reserve have rolled out the red carpet for fast-growing companies looking to borrow at extremely cheap rates. As we move headlong into the second quarter, the following three growth stocks stand out for having all the tools needed to make investors a lot richer.

  • Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
    Zacks

    Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA

    The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.

  • Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
    Business Wire

    Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

    Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. As a next-generation tissue factor-targeting antibody-drug conjugate (ADC), XB002 has the potential for an improved therapeutic index and may provide a favorable safety profile compared with earlier-generation tissue factor-targeting ADCs.